Evidence map›Paper›PMID 38931890›Full record

ReviewPharmaceutics2024

The Integration of Advanced Drug Delivery Systems into Conventional Adjuvant Therapies for Peri-Implantitis Treatment.

Iria Seoane-Viaño, Mariola Seoane-Gigirey, Carlos Bendicho-Lavilla, Luz M Gigirey, Francisco J Otero-Espinar, Santiago Seoane-Trigo

Abstract readReview
In one paragraph

Review in Pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Iria Seoane-ViañoDepartment of Pharmacology, Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, and Institute of Materials (iMATUS), University of Santiago de Compostela (USC), 15782 Santiago de Compostela, Spain.ORCID 0000-0003-3910-2074
Mariola Seoane-GigireyDepartment of Pharmacology, Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, and Institute of Materials (iMATUS), University of Santiago de Compostela (USC), 15782 Santiago de Compostela, Spain.
Carlos Bendicho-LavillaDepartment of Pharmacology, Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, and Institute of Materials (iMATUS), University of Santiago de Compostela (USC), 15782 Santiago de Compostela, Spain.ORCID 0000-0001-6425-2862
Luz M GigireyDepartment of Applied Physics, Faculty of Optics and Optometry, University of Santiago de Compostela (USC), 15782 Santiago de Compostela, Spain.
Francisco J Otero-EspinarDepartment of Pharmacology, Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, and Institute of Materials (iMATUS), University of Santiago de Compostela (USC), 15782 Santiago de Compostela, Spain.ORCID 0000-0001-9030-2253
Santiago Seoane-TrigoPh. Dr. Adult Comprehensive Dentistry, University of Santiago de Compostela (USC), 15782 Santiago de Compostela, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the high success rates of dental implants, peri-implantitis is currently the most common complication in dental implantology. Peri-implantitis has an inflammatory nature, it is associated with the accumulation of plaque in the peri-implant tissues, and its evolution can be progressive depending on various factors, comorbidities, and poor oral health. Prophylaxis and different treatment methods have been widely discussed in recent decades, and surgical and non-surgical techniques present both advantages and disadvantages. In this work, a literature review of different studies on the application of adjuvant treatments, such as local and systemic antibiotics and antiseptic treatments, was conducted. Positive outcomes have been found in the short (up to one year after treatment) and long term (up to ten years after treatment) with combined therapies. However, there is still a need to explore new therapies based on the use of advanced drug delivery systems for the effective treatment of peri-implantitis in the long term and without relapses. Hence, micro- and nanoparticles, implants, and injectable hydrogels, among others, should be considered in future peri-implantitis treatment with the aim of enhancing overall therapy outcomes.

Indexed as

adjuvant therapiesbleeding on probingdental implant surface and periodontal pocketimplants and injectable hydrogelsnanoparticles and microparticlesperi-implantitis

Identifiers

PMID38931890
PMCPMC11207621

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.